Abstract
Background
Pulmonary hypertension (PH) is a complex syndrome characterized by increased pulmonary arterial pressure and classified into five groups, according to dyspnea on exertion and systemic muscle dysfunction. These symptoms can be identified using the sit-to-stand test (STS), which indirectly evaluates exercise tolerance and lower limb muscle strength. Previous studies used the STS in PH; however, psychometric properties to understand and validate this test were not described for patients with PH.
Objective
To evaluate the psychometric properties (validity, reliability, and responsiveness) of different STS protocols in patients with PH.
Methods and analyses
This is a systematic review protocol that will include studies using STS in patients with PH. Searches will be conducted on PubMed/MEDLINE, EMBASE, SciELO, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science databases following PICOT mnemonic strategy and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P). Rayyan software will be used for study selection. The Risk of bias will be assessed using the Consensus‐Based Standards for the Selection of Health Measurement Instruments (COSMIN) tool, while the quality of evidence will be assessed using the modified Grading of Recommendations, Assessment, Development, and Evaluation (GRADE). Two researchers will independently conduct the study, and a third researcher will be consulted in case of disagreement. The psychometric properties will be evaluated according to the COSMIN. This protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO, no. CRD42021244271).
Citation: Cardoso NL, de Sá JF, do Nascimento LFE, Mendes LA, Bruno S, Torres-Castro R, et al. (2022) Psychometric properties of the sit-to-stand test for patients with pulmonary hypertension: A systematic review protocol. PLoS ONE 17(10): e0275646. https://doi.org/10.1371/journal.pone.0275646
Editor: Fatih Özden, Mugla Sitki Kocman Universitesi, TURKEY
Received: November 30, 2021; Accepted: September 10, 2022; Published: October 5, 2022
Copyright: © 2022 Cardoso et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The article does not report data, and the data availability policy is not applicable.
Funding: This study will be financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior Brasil (CAPES) finance Code 001, student Natália Lopes Cardoso. Vanessa Regiane Resqueti is a fellow of the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) – process number 305960/2021-0. Guilherme Augusto de Freitas Fregonezi is fellow of the CNPq – process number 316937/2021-5. The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Pulmonary hypertension (PH) is a complex clinical syndrome composed of progressive heterogeneous conditions that increase pulmonary arterial pressure and pulmonary vascular resistance. These symptoms are common to certain diseases that tend to evolve with right heart failure, reduced exercise tolerance, and early death of patient [1]. The current classification of PH is divided into five groups considering clinical data, pathophysiology, anatomopathological findings, and hemodynamic parameters [1–3].
Symptoms in patients with PH are non-specific and may lead to late diagnosis [4]. Progressive dyspnea on exertion is the earliest and most common symptom, reflecting the inability of the cardiovascular system to increase cardiac output during exertion. Other possible symptoms are fatigue, pre-syncope, chest pain, and palpitations [5]. At muscular level, patients present systemic muscle dysfunction and increased risk of functional decline due to loss of muscle function [6]. Exercise tolerance can be evaluated using different instruments, such as sit-to-stand test (STS) protocols [7, 8]. STS has several protocols, such as the five-repetition STS (5R-STS), the thirty-second STS (30S-STS), and the one-minute STS (1M-STS), and is also widely used to indirectly evaluate lower limb muscle strength [9], mobility, and functional independence [10].
STS evaluates exercise tolerance in several populations, including elderlies [11, 12] and patients with chronic respiratory conditions, such as chronic obstructive pulmonary disease [8, 13, 14], cystic fibrosis [15], and PH [16, 17]. Furthermore, reference values for healthy individuals [18] are widely used. Recently strong correlations were observed between 1M-STS and both daily step count and distance walked on the six-minute walk test (6MWT) in patients with PH [17]. Accordingly, this test is interesting and valuable, mainly because 1M-STS is easily performed, requires no special infrastructure, and induces less hemodynamic stress than 6MWT [19]. Thus, how the 30S-STS which a study also evaluated as reliable and valid for patients with PH [16]. Despite this easy application and clinical importance, there is no previous systematic review on the STS in the HP population, showing the gap found in the literature. This variety of STS protocols makes it important to understand the psychometric properties of the instruments used to measure exercise tolerance in HP. The evaluation of psychometric properties makes it possible to select and understand the instruments that will provide us with valid and reliable measurements [20], based on the Consensus-Based Standards for the Selection of Health Measurement Instruments which describes how properties should be handled and described [21].
Thus, this systematic review aims to identify the available evidence regarding STS in different PH groups and present psychometric properties (validity [criterion validity, construct validity], reliability [internal consistency and measurement error], and responsiveness) and number of repetitions achieved in different STS protocols. Results will help rehabilitation professionals safely interpret these measurements, supporting their use in clinical practice.
Methods
Registration and reporting of review findings
The systematic review will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) [22] (S1 Appendix). This protocol will also follow PICOT mnemonic strategy, while the risk of bias will be assessed using the Consensus-Based Standards for the Selection of Health Measurement Instruments (COSMIN) [23, 24]. The protocol was submitted and registered in the International Prospective Register of Systematic Reviews (PROSPERO, no. CRD42021244271).
Eligibility criteria
Will be included studies of any type of randomized clinical trials or randomized controlled trials, besides observational studies (prospective, retrospective, longitudinal, or case-control) published in English. We will consider studies conducted at a hospital, outpatient, or primary care setting.
Exclusion criteria will be as follows: systematic reviews, in vitro studies, conference abstracts, theses, dissertations, literature reviews, studies conducted with children or mixed populations, and studies in which STS protocol did not meet the criteria described by Kahraman et al. (2020) [16], and those in which data from patients with PH were not analyzed separately or could not be extracted or obtained even after contacting authors.
Characteristics of participants
We will include studies with adults participants with a clinical diagnosis of PH (i.e., resting mean pulmonary arterial pressure ≥ 25 mmHg or systolic pulmonary arterial pressure > 40 mmHg assessed using right cardiac catheterization or echocardiography) [3] or diagnosed by a specialist physician. Analyses will consider subgroups according to PH classification: pulmonary arterial hypertension, PH due to left heart disease, PH due to lung diseases or hypoxia or both, chronic thromboembolic PH and other pulmonary artery obstructions, and PH due to unknown or multifactorial mechanisms [1].
Type of intervention
We will include studies that assess exercise tolerance using STS (30S-STS, 1M-STS, or 5R-STS), according to Kahraman et al. (2020) [16].
Type of outcome measures
Primary outcomes.
Psychometric properties (validity [criterion validity, construct validity], reliability [internal consistency and measurement error], and responsiveness) and repetitions achieved in STS protocols by participants with PH.
Secondary outcomes.
- Association between STS and patient-reported outcomes (PROM) (e.g., symptoms, health-related quality of life, nocturnal symptoms, anxiety levels, and depression);
- Reported symptoms during STS protocols using Borg scale;
- Changes in respiratory or cardiovascular system in response to STS protocols before and after intervention (e.g., changes in peripheral arterial oxygen saturation or heart rate).
Search strategy
Titles and abstracts will be screened on PubMed/MEDLINE, EMBASE, SciELO, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science databases with no time restriction set for publications. We will use a combination of descriptors and the Medical Subject Headings (MeSH) to incorporate primary elements from the research question, including the construction, the population, and the type of intervention [21]. The searching strategy for all databases was added as a supplementary file with this protocol (S2 Appendix).
Data collection and analysis
Two researchers (NLC and LN) will independently screen the titles and abstracts of the studies and will remove the irrelevant studies. A third researcher (JFS) will evaluate any discrepancies and will advise in case of disagreement. Studies screened will be inserted into Rayyan [25] software (pre-selection of duplicates) and confirmed manually according to eligibility criteria. Full text of eligible studies will be attached to Rayyan software and screened by the same researchers (NLC and LN). In case of disagreement, the third researcher (JFS) will be consulted. Reasons for exclusion will be recorded, and screening will be summarized in a PRISMA flowchart (S1 Fig).
Data extraction and management
The COSMIN data extraction form related to measurement properties [21] will be used by two researchers (NLC and LN) to independently extract all data. We will solve any disagreements by discussion with a third researcher (JFS). Therefore, essential information will be extracted from studies to fill boxes from the checklist. The results will be quantitatively pooled or qualitatively summarized [21].
Risk of bias assessment
Two researchers (NLC and LN) will independently analyze the methodological quality of studies using COSMIN risk of bias checklist [26, 27]. We will solve any disagreements on the risk of bias assessment by discussion with a third researcher (JFS). Each consistent result will be grouped quantitatively or summarized qualitatively and compared to criteria for good measurement properties, interpreted as very good, adequate, doubtful, or inadequate. Methodological quality of each single study on a measurement property will be included in a summary of findings table [27, 28]. Next, results of every single study on a measurement property will be rated against updated criteria for good measurement properties as sufficient (+), insufficient (-), or indeterminate (?) [26].
Assessment of quality of evidence
The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) will be used to assess the quality of evidence of the systematic review. Evidence will be classified as high, moderate, low, or very low [26], based on risk of bias, inconsistency, imprecision, and indirectness [29].
Data synthesis
We will use the Odds Ratio, Relative Risk or Risk Difference for the analysis of dichotomous data, for the continuous variables they will be presented as means, medians, and standard deviations. In the case of performing a quantitative synthesis (meta-analysis), we will use RevMan V.5.3.528 software for homogeneous studies. In case of missing data, we will contact the authors to obtain the data.
We plan to carry out subgroup analyses, with the type of PH and another subgroup analysis for the different STS protocols. If necessary, we will perform sensitivity analyses to examine the effects of methodological quality in the pooled estimate, removing studies that are rated at high risk of bias.
Discussion
Patients with PH present exercise intolerance; therefore, STS is a simple and advantageous instrument because protocols are faster and elicit less hemodynamic stress than other field tests. The systematic review will identify validity (criterion validity, construct validity), reliability (internal consistency and measurement error), and responsiveness.
These properties will also help interpret and compare STS and field tests (e.g., 6MWT) in clinical practice of these patients. In addition, identifying STS as a valid, reproductive, and responsive measure may also increase knowledge regarding intrinsic characteristics of the test in different types of PH and support better indication of STS characteristics and adaptation of patients with PH to exercise. Thus, this systematic review will determine the importance of STS to develop standard protocols and improvements health services.
References
- 1. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2016, v. 37, n. 1, p. 67–119.
- 2. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913. pmid:30545968
- 3. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34–41. pmid:24355639
- 4. Lapa MS, Ferreira EV, Jardim C, Martins Bdo C, Arakaki JS, Souza R. Clinical characteristics of pulmonary hypertension patients in two reference centers in the city of São Paulo. Rev Assoc Med Bras. 2006. 52:p.139–143
- 5. Rose-Jones LJ, McLaughlin VV. Pulmonary hypertension: types and treatments. Curr Cardiol Rev. 2015; 11: 73–79. pmid:24251459
- 6. Batt J, Ahmed SS, Correa J, Bain A, Granton J. Skeletal muscle dysfunction in idiopathic pulmonary arterial hypertension. Am. J. Respir. Cell Mol. Biol.v50, 74–86, 2014. pmid:23972212
- 7. Jones SE, Kon SS, Canavan JL, Patel MS, Clark AL, Nolan CM, et al. The five-repetition sit-to-stand test as a functional outcome measure in COPD. Thorax. 2013;68(11):1015–1020. pmid:23783372
- 8. Morita AA, Bisca GW, Machado FVC, Hernandes NA, Pitta F, Probst VS. Best Protocol for the Sit-to-Stand Test in Subjects With COPD. Respir Care. 2018 Aug; 63(8):1040–1049. pmid:29789413
- 9. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently 19 healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc. 2011;43(7):1334–1359.
- 10. Pollock A, Gray C, Culham E, Durward BR, Langhorne P. Interventions for improving sit-to stand ability following stroke. Cochrane Database Syst Rev. 2014;(5):CD007232. pmid:24859467
- 11. Kuo YL. The influence of chair seat height on the performance of community-dwelling older adults’ 30-second chair stand test. Aging Clin Exp Res. 2013 Jun; 25(3):305–309. pmid:23740582
- 12. Melo TA, Duarte AC, Bezerra TS, França F, Soares NS, Brito D. Teste de Sentar-Levantar Cinco Vezes: segurança e confiabilidade em pacientes idosos na alta da unidade de terapia intensiva. Rev Bras Ter Intensiva. 2019;31(1):27–33. pmid:30892478
- 13. Vaidya T, Chambellan A, de Bisschop C. Sit-to-stand tests for COPD: A literature review. Respir Med. 2017 Jul; 128():70–77. pmid:28610673
- 14. Kakavas S, Papanikolaou A, Kompogiorgas S, Stavrinoudakis E, Karayiannis D, Balis E. The Correlation of Sit-to-Stand Tests with COPD Assessment Test and GOLD Staging Classification. COPD. 2020 Dec;17(6):655–661. pmid:33023324
- 15. Combret Y, Boujibar F, Gennari C, Medrinal C, Sicinski S, Bonnevie T, et al. Measurement properties of the one-minute sit-to-stand test in children and adolescents with cystic fibrosis: A multicenter randomized cross-over trial. PLoS One. 2021 Feb 12;16(2):e0246781. pmid:33577586
- 16. Kahraman BO, Ozsoy I, Akdeniz B, Ozpelit E, Sevinc C, Acar S, et al. Test-retest Reliability and Validity of the Timed Up and Go Test and 30-second Sit to Stand Test in Patients With Pulmonary Hypertension. Int J Cardiol. 2020 Apr 1;304:159–163. pmid:31980271
- 17. Nakazato L, Mendes F, Paschoal IA, Oliveira DC, Moreira MM, Pereira MC. Association of daily physical activity with psychosocial aspects and functional capacity in patients with pulmonary arterial hypertension: a cross-sectional study. Pulm Circ. 2021 Mar 29;11(2):2045894021999955. pmid:33854767
- 18. Strassmann A, Steurer-Stey C, Lana KD, Zoller M, Turk AJ, Suter P, et al. Population-based reference values for the 1-min sit-to-stand test. Int J Public Health. 2013;58(6):949–953. pmid:23974352
- 19. Ozalevli S, Ozden A, Itil O, Akkoclu A. Comparison of the Sit-to-Stand Test with 6 min walk test in patients with chronic obstructive pulmonary disease. Respir Med. 2007 Feb; 101(2):286–293. pmid:16806873
- 20. Souza AC, Alexandre NMC, Guirardello EB. Propriedades psicométricas na avaliação de instrumentos: avaliação da confiabilidade e da validade. Epidemiol. Serv. Saúde. Brasília, 26(3):649–659, jul-set 2017.
- 21. Mokkink LB, Prinsen CAC, Patrick DL, Alonso J, Bouter LM, Vet HCW, et al. COSMIN methodology for systematic reviews of Patient‐Reported Outcome Measures (PROMs). Use manual 2018. Available from: www.cosmin.nl
- 22. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. pmid:25554246
- 23. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010 May;19(4):539–549. pmid:20169472
- 24. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol. 2010;63(7):737–745. pmid:20494804
- 25. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Systematic Reviews (2016) 5:210. pmid:27919275
- 26. Mokkink LB, Boers M, van der Vleuten CPM, Bouter LM, Alonso J, Patrick DL, et al. COSMIN Risk of Bias tool to assess the quality of studies on reliability or measurement error of outcome measurement instruments: a Delphi study. BMC Medical Research Methodology. 2020;20(293). pmid:33267819
- 27. Mokkink LB, Prinsen CAC, Patrick DL, Alonso J, Bouter LM, Vet HCW, et al. COSMIN Study Design checklist for Patient-reported outcome measurement instruments. User manual 2019. Available from: www.cosmin.nl
- 28. Prinsen CAC, Mokkink LB, Bouter LM, Alonso J, Patrick DL, de Vet HCW, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res. 2018;27(5):1147–1157. pmid:29435801
- 29. Mokkink LB, Terwee CB, Knol DL, Stratford PW, Alonso J, Patrick DL, et al. The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol. 2010 Mar 18;10:22. pmid:20298572